Summary Sublines of a human myeloid leukaemia cell line, KBM-3, with increasing degrees of resistance to the antileukaemic agent 4'-(9-acridinlylamino) methanesulphon-m-anisidide (m-AMSA) were evaluated for their response to this drug using a clonogenic assay to measure cell survival and alkaline elution to assess m-AMSA induced DNA strand breakage. Polyacrylamide gel electrophoresis was used to map the protein profiles of the various cell lines. The resistant lines were obtained by intermittent exposure of the KBM-3 cells to the highest tolerated concentration of m-AMSA so that the culture would be repopulated only by the most resistant subpopulation after each exposure. Two distinct phases were apparent during the development of resistance. During the first 14 months of intermittent exposure to maximally tolerated concentrations of m-AMSA, the cells developed low-degree m-AMSA resistance (5-7- HL-60 (Collins et al., 1977; Gallagher et al., 1979) have been used to generate models of resistance to the antileukaemic agent 4'-(9-acridinylamino) methanesulphonm-anisidide (m-AMSA) (Odaimi et al., 1986; . Our previous studies of HL-60/AMSA showed that the highly resistant cells had significantly fewer m-AMSA induced topoisomerase II mediated DNA strand breaks than the drug sensitive parent line (Bakic et al., 1986) .
The emergence of drug resistance during the treatment of malignant disease continues to be a major reason for therapeutic failure. Understanding the cellular mechanisms for the development of drug resistance is therefore of major importance for the successful circumvention of this problem. Such mechanistic studies are greatly facilitated by the availability of continuously growing tumour cell lines with experimentally induced resistance to different antineoplastic agents.
Human acute myelogenous leukamia (AML) cell lines such as HL-60 (Collins et al., 1977; Gallagher et al., 1979) have been used to generate models of resistance to the antileukaemic agent 4'-(9-acridinylamino) methanesulphonm-anisidide (m-AMSA) (Odaimi et al., 1986; . Our previous studies of HL-60/AMSA showed that the highly resistant cells had significantly fewer m-AMSA induced topoisomerase II mediated DNA strand breaks than the drug sensitive parent line (Bakic et al., 1986) .
Since it has not been established whether the observed decrease in m-AMSA induced DNA strand breakage is a general mechanism for m-AMSA resistance in human AML or a phenomenon uniquely associated with the highly resistant HL-60 cell line, we expanded our investigation to a second human AML cell line, KBM-3. It is also questionable whether the phenomena observed in highly resistant cell lines can completely explain the lower degrees of resistance that are likely to be observed in a clinical situation. We therefore examined several sublines of KBM-3 with increasing degrees of resistance to m-AMSA. We used the alkaline elution technique to measure DNA strand scission in each of these cell lines after exposure to various concentrations of m-AMSA and correlated the results with the phenotypic expression of resistance as measured by clonogenic assay.
In a preliminary study we analysed total cellular proteins from HL-60, KBM-3 and their respective high-degree m-AMSA resistant sublines; these initial results suggested the disappearance of a specific protein band with a molecular mass of 76 kDa in the highly resistant sublines, although no temporal relationship between the development of m-AMSA resistance and the disappearance of the protein was established (Kohli et al., 1987 (Laemmli, 1970;  O 'Farrel & O'Farrel, 1977) , using a Bio-Rad Protean II gel electrophoresis apparatus (Bio-Rad Inc., Richmond, CA, USA). Proteins were visualised by staining with Coomassie brilliant blue, followed by destaining.
Results
The resistant phenotypes in the KBM-3 cell lines were developed through intermittent exposure to maximally tolerated concentrations of m-AMSA. Sublines from the specific time-points indicated on the curve in Figure 1 were analysed for their response to m-AMSA by alkaline elution and cloning and for their protein content by PAGE. The results of the survival studies on KBM-3 and its resistant sublines after a 60 min exposure to various concentrations of m-AMSA are shown in Figure 2 . The colony forming ability of all cell lines decreased progressively upon exposure to increasing concentrations of m-AMSA. The IC50 values showed a 7-fold increase from the parent KBM-3 line up to the KBM-3/AMSA 10 subline, at which point a pronounced shift was observed, reflected by the dramatic increase in the resistance index for the KBM-3/AMSA 12.5, KBM-3/AMSA 15, and KBM-3/AMSA 20 sublines (Table  I ). In fact, the marked increase in resistance index between KBM-3/AMSA 10 and KBM-3/AMSA 12.5 occurred following a single escalation of the m-AMSA retreatment concentration.
We used the sensitive alkaline elution method to compare the level of DNA strand break induction in the KBM-3 cell line and its m-AMSA-resistant sublines, since previous studies had shown that the highly resistant HL-60/AMSA phenotype exhibited a markedly reduced level of m-AMSA induced DNA strand breakage (Bakic et al., 1986) . The compiled dose-response curves for the parent KBM-3 line and for four sublines with increasing degrees of resistance to m-AMSA are displayed in Figure 3 . The two low-degree resistance sublines, KBM-3/AMSA 6.25 and KBM-3/AMSA 10, had slightly depressed levels of DNA strand breaks compared with the parent line. In these two sublines, and in the parent line, the maximum level of DNA breakage was achieved with an m-AMSA concentration of about 0.5 ELM. A dramatic change in DNA breakage frequency was observed between the KBM-3/AMSA 10 and KBM-3/AMSA 12.5 sublines; the highly resistant phenotype, exemplified by KBM-3 AMSA 12.5, KBM-3/AMSA 15 and KBM-3/AMSA 20, manifested a complete absence of m-AMSA induced DNA strand breaks over this same range of drug concentration (i.e. Figure 4 shows a representative set of the elution profiles used to generate the data in Figure 3 . The elution profiles of the KBM-3/AMSA 10 subline and of the KBM-3/AMSA 12.5 subline (which was developed from KBM-3/AMSA 10 cells following a single escalation of the m-AMSA retreatment concentration) clearly illustrate the pronounced transition in susceptibility to the DNA-damaging effects of m-AMSA that occurred between these particular degrees of resistance.
The results of PAGE analysis for cytoplasmic protein content are shown in Figure 5 . The most obvious change was the loss of a 76 kDa protein band, which disappeared from the cells at the same point at which high-degree resistance was observed with alkaline elution and cloning, i.e. at the transition from the KBM-3/AMSA 10 to the KBM-3/AMSA 12.5 subline. Other minor alterations in the protein profiles could be discerned, although these changes were somewhat variable and were impossible to quantitate in a one-dimensional system.
Discussion
The introduction of m-AMSA into clinical trials in 1978 provided a therapeutic alternative for anthracycline-resistant AML, producing complete remissions in about 25-30% of the patients (Legha et al., 1980 (Legha et al., , 1982 . In addition, m-AMSA in combination with l-B-D-arabinofuranosylcytosine (Ara-C) produced complete remissions in 70-75% of previously untreated patients with AML (Keating et al., 1987) . Unfortunately, these figures have not been translated into a substantial prolongation of remissions or an increased cure rate. When the leukaemia recurs, drug resistance continues to be a major clinical obstacle.
Studies of the mechanism of m-AMSA cytotoxicity have The 76 kDa protein is marked with an arrow. The pattern for KBM-3/AMSA 20 was identical to that for KBM-3/AMSA 15, but has been omitted for clarity. Table I IC50 focused on the role of the interaction between the drug and DNA topoisomerase II in the production of m-AMSA induced DNA strand breaks. Such studies have indicated an altered interaction between m-AMSA and DNA topoisomerase II in human m-AMSA resistant leukaemia (Bakic et al., 1986; Estey et al., 1987) . Such mechanistic studies, however, have all been carried out with highly resistant leukaemic cells.
The current investigation used a clonogenic assay, alkaline elution and PAGE to study potentially more clinically relevant sublines of KBM-3 with various degrees of m-AMSA resistance. Our data demonstrate two distinct phases in the development of resistance to m-AMSA in this human AML line. The first of these phases, corresponding to the first 440 days of intermittent exposure to maximally tolerated concentrations of m-AMSA, was characterised by up to 7-fold increase in the resistance index and a small but measurable decrease in the efficiency of DNA strand breakage by m-AMSA (Figures 2 and 3 , Table I ). The second phase, characterised by a dramatic increase in resistance index and a virtual absence of detectable DNA strand breakage after exposure of the cells to the same range of test m-AMSA concentrations that produced a high level of strand breakage in the parent KBM-3 line, occurred between the KBM-3/AMSA 10 and the KBM-3/AMSA 12.5 sublines over a short period of time (between days 440 and 480) (Figures 1  and 4) . The magnitude of m-AMSA induced DNA strand breakage observed using alkaline elution therefore qualitatively paralleled the resistance index obtained from the cloning data.
Because the design of the experimental protocol for the development of m-AMSA resistance will result in the elimination of all sensitive cells from the culture (as a result of the extremely cytotoxic concentrations of m-AMSA used), the cells within any given population (e.g. KBM-3/AMSA 10) appear to have a relatively uniform resistance to the drug, as indicated by the observations that (i) the elution profiles for highly damaged DNA from such cells (e.g. Figure 4 ) were essentially linear even after more than 95% of the DNA had been eluted, with no evidence of a resistant tail, and (ii) the survival curves for lines of low-degree resistance also showed no evidence of a resistant tail even at surviving fractions < 1% (Figure 2) . PAGE analysis of the KBM-3/AMSA cell lines with increasing degrees of resistance revealed the sudden disappearance of a 76 kDa protein band between the KBM-3/ AMSA 10 and KBM-3/AMSA 12.5 sublines (Figure 5 ), i.e. precisely where the transition from low to high-degree resistance occurred. The temporal correlation between the development of the high-degree resistance phenotype and the altered levels of this protein suggests that these two events may be related.
There are several possible explanations for these observations. First, the early development of low-degree resistance may represent either a gradual cellular adaptation to the stress of intermittent drug exposure or a single event occurring at some time during this period. It is not possible at present to discriminate between these two alternatives, although the fact that the maximally tolerated m-AMSA concentration did increase progressively with time (Figure 1) favours the former explanation. The more rapid late phase, during which the high-degree resistance phenotype developed concomitantly with a decrease in m-AMSA induced DNA single-strand breaks and the disappearance of the 76kDa protein, may be a result of a separate genetic mutation.
Alternatively, the observed two phases in the development of m-AMSA resistance may have a common underlying mutational event. The observed development of high-degree resistance at approximately 440 days could result from overexpression or amplification of this mutated gene, causing a suppression of the 76 kDa protein. In this case, both low and high-degree m-AMSA resistance would be stable phenotypic changes. The level of the 76 kDa protein may indeed already be decreased in the cells with low-degree m-AMSA resistance. However, the sensitivity of our PAGE procedure did not allow the resolution of possible minor changes in 76 kDa protein levels; only the major change concomitant with the cellular transition to a high-degree resistance phenotype could be detected with certainty.
The underlying mechanism(s) of the observed phenomena are therefore at present unknown. That a mutational event is involved at some point is supported by the observation that the HL-60/AMSA and KBM-3/ AMSA high-degree resistance phenotypes (unpublished data) are extremely stable, with little or no reversion to an m-AMSA sensitive phenotype on prolonged culturing without further exposure to the drug. The data suggest a strong temporal correlation between the development of a stable high-degree resistance phenotype, acquisition of refractoriness to m-AMSA induced DNA-strand breakage, and the loss of the 76 kDa protein, implying a possible role for this protein in the cytotoxic activity of m-AMSA. Studies are under way in our laboratory on the nature and function(s) of the protein and the (genetic ?) event(s) underlying its disappearance from leukaemia cells that become highly m-AMSA resistant. The possibility of separate mechanisms for highdegree as opposed to low-degree resistance to the drug, which may be clinically more relevant, is being considered. Studies with clonal populations -e.g. an examination of strand breakage and 76 kDa protein levels in subclones of the KBM-3/AMSA 10 subline -will ultimately clarify many of these questions, as will studies of the stability of the resistance in each of these sublines and their subclones. Clearly, a complete definition of the mechanisms of m-AMSA resistance in AML cells await the outcome of such studies.
